Selected Recent Publications
The dynamics of an immunotherapy duo. Nat Cancer. 2022 Apr;3(4):376-378. doi: 10.1038/s43018-022-00362-5. PMID: 35484417.
BHLHE40 Regulates T Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. Cancer Immunol Res, 2022. May 3;10(5):597-611. PMID: 35181783
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell. e-Pub 2020. PMID: 32783918.
. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574(7780):696-701, 2019. e-Pub 2019. PMID: 31645760.
. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell 175(4):1014-1030.e19, 2018. e-Pub 2018. PMID: 30343900.
. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell 175(5):1443, 2018. PMID: 30445041.
. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. Nat Commun 8(1):562, 2017. e-Pub 2017. PMID: 28916749.
. The RNA-Binding Protein HuR Posttranscriptionally Regulates IL-2 Homeostasis and CD4+ Th2 Differentiation. Immunohorizons 1(6):109-123, 2017. PMID: 30035254.
. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res 5(2):106-117, 2017. e-Pub 2017. PMID: 28073774.
. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Adv Immunol 130:25-74, 2016. e-Pub 2016. PMID: 26922999.
. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 125(9):3413-21, 2015. e-Pub 2015. PMID: 26258412.
. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162(6):1229-41, 2015. e-Pub 2015. PMID: 26321679.
. Transcriptomic-Wide Discovery of Direct and Indirect HuR RNA Targets in Activated CD4+ T Cells. PLoS One 10(7):e0129321, 2015. e-Pub 2015. PMID: 26162078.
. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528):577-81, 2014. PMID: 25428507.
. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol 27:16-25, 2014. e-Pub 2014. PMID: 24531241.
. Conditional knockout of the RNA-binding protein HuR in CD4? T cells reveals a gene dosage effect on cytokine production. Mol Med 20:93-108, 2014. e-Pub 2014. PMID: 24477678.
. Posttranscriptional gene regulation of IL-17 by the RNA-binding protein HuR is required for initiation of experimental autoimmune encephalomyelitis. J Immunol 191(11):5441-50, 2013. e-Pub 2013. PMID: 24166976.
. Incisional hernia recurrence through genomic profiling: a pilot study. Hernia 17(2):193-202, 2013. e-Pub 2012. PMID: 22648066.
. Method for the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts using RIP-Chip. J Vis Exp(67), 2012. e-Pub 2012. PMID: 23051702.
. Coordinate regulation of GATA-3 and Th2 cytokine gene expression by the RNA-binding protein HuR. J Immunol 187(1):441-9, 2011. e-Pub 2011. PMID: 21613615.
. Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle 9(16):3337-46, 2010. e-Pub 2010. PMID: 20724828.
. The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer. BMC Cancer 10:126, 2010. e-Pub 2010. PMID: 20370918.